Thiamethoxam induced mouse liver tumors and their relevance to humans. Part 1: mode of action studies in the mouse.
Thiamethoxam, a neonicotinoid insecticide, which is not mutagenic either in vitro or in vivo, caused an increased incidence of liver tumors in mice when fed in the diet for 18 months at concentrations in the range 500 to 2500 ppm. A number of dietary studies of up to 50 weeks duration have been conducted in order to identify the mode of action for the development of the liver tumors seen at the end of the cancer bioassay. Both thiamethoxam and its major metabolites have been tested in these studies. Over the duration of a 50-week thiamethoxam dietary feeding study in mice, the earliest change, within one week, is a marked reduction (by up to 40%) in plasma cholesterol. This was followed 10 weeks later by evidence of liver toxicity including single cell necrosis and an increase in apoptosis. After 20 weeks there was a significant increase in hepatic cell replication rates. All of these changes persisted from the time they were first observed until the end of the study at 50 weeks. They occurred in a dose-dependent manner and were only observed at doses (500, 1250, 2500 ppm) where liver tumors were increased in the cancer bioassay. There was a clear no-effect level of 200 ppm. The changes seen in this study are consistent with the development of liver cancer in mice and form the basis of the mode of action. When the major metabolites of thiamethoxam, CGA322704, CGA265307, and CGA330050 were tested in dietary feeding studies of up to 20 weeks duration, only metabolite CGA330050 induced the same changes as those seen in the liver in the thiamethoxam feeding study. It was concluded that thiamethoxam is hepatotoxic and hepatocarcinogenic as a result of its metabolism to CGA330050. Metabolite CGA265307 was also shown to be an inhibitor of inducible nitric oxide synthase and to increase the hepatotoxicity of carbon tetrachloride. It is proposed that CGA265307, through its effects on nitric oxide synthase, exacerbates the toxicity of CGA330050 in thiamethoxam treated mice.
Green
Trevor
T
Syngenta Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire, United Kingdom. trevor.green@syngenta.com
Toghill
Alison
A
Lee
Robert
R
Waechter
Felix
F
Weber
Edgar
E
Noakes
James
J
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002273:Carcinogens / Q000633:toxicity*; D002455:Cell Division / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D004032:Diet; D004305:Dose-Response Relationship, Drug; D020287:In Situ Nick-End Labeling; D008114:Liver Neoplasms, Experimental / Q000139:chemically induced* / Q000473:pathology; D008297:Male; D051379:Mice; D000073943:Neonicotinoids; D009574:Nitro Compounds / Q000097:blood / Q000633:toxicity*; D009929:Organ Size / Q000187:drug effects; D010078:Oxazines / Q000097:blood / Q000633:toxicity*; D010575:Pesticides / Q000097:blood / Q000633:toxicity*; D000077922:Thiamethoxam; D013844:Thiazoles
D002273:Carcinogens; D000073943:Neonicotinoids; D009574:Nitro Compounds; D010078:Oxazines; D010575:Pesticides; D013844:Thiazoles; D000077922:Thiamethoxam; D002784:Cholesterol